A Serum Metabolomic Study Reveals Changes in Metabolites During the Treatment of Lung Cancer-Bearing Mice with Anlotinib

Figures & data

Figure 1 Typical TICs of metabolic profiles in the anlotinib and control groups. (A) The anlotinib group in positive ion mode. (B) The anlotinib group in negative ion mode. (C) The control group in positive ion mode. (D) The control group in negative ion mode.

Figure 2 (A) PCA score plot and (B) OPLS-DA score plot between the anlotinib and control groups. The blue points represent the samples in the anlotinib group, and the red points represent the samples in the control group. (C) The 200 permutation test.

Table 1 Metabolites and Their Related Metabolic Pathways in the Anlotinib and Control Groups

No.	Metabolites	VIP value	P-value	Fold Change
1	Myristic acid	1.529	0.001	1.551
2	Cytidine	1.551	0.001	3.187
3	Indole	1.575	0.003	3.865
4	Deoxycytidine	1.377	0.000	2.958
5	Dimethylglycine	1.205	0.001	1.854
6	Cytosine	1.314	0.000	2.117
7	Tetracosanoic acid	1.456	0.003	1.710
8	Behenic acid	1.393	0.003	1.742
9	L-Gulonic gamma-lactone	1.429	0.003	1.537
10	Glycyl-L-leucine	1.466	0.017	1.791
11	6-Hydroxymelatonin	1.484	0.001	2.858
12	N-Formylmethionine	1.486	0.008	2.307
13	Glutathione disulfide	1.499	0.008	1.778

Notes: All values retain 3 decimal places.

Figure 3 Pathway enrichment analysis and summary of pathway impact based on KEGG pathway networks.